Sana Biotechnology Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Sana Biotechnology Inc 's ROA in the third quarter of 2026?
Sana Biotechnology Inc recorded a cumulative net loss of $-149 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -32.89%.

However, within the Healthcare sector 470 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 4065, from total ROA ranking in the second quarter of 2026 at 4714.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	-5.03 %	69.03 %	-16.14 %	-6.51 %	-12.88 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-149	-212	-242	-244	-234
Return On Assets (TTM)	-32.89 %	-46.12 %	-60.97 %	-58.86 %	-55.53 %
SANA's Total Ranking	# 4065	# 4714	# 4089	# 4141	# 4038
Total Assets (TTM) in million	414	611	374	417	435
Seq. Total Assets Change	-32.36 %	63.63 %	-10.39 %	-4.26 %	20.4 %
Seq. Net Income Change	-	-	-	-	-

SANA's 5 Years Annual ROA >> Back to SANA Management Effectiveness >> Compare SANA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 55
Sector	# 471
Overall	# 3739

Return On Assets Statistics
High	Average	Low
18.33 %	-37.07 %	-60.97 %
(Sep 30 2021)		(Mar 31 2026)

Financial Statements
Sana Biotechnology Inc 's Assets	$ 414 million	SANA's Balance sheet
Sana Biotechnology Inc 's Income	$ 20 million	Quarterly SANA's Income Statement
SANA's Income by Division		See SANA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-6.51 %	-9.55 %	-59.2 %	17.62 %	-
Total Assets in million	417	446	493	1,208	1,027
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-244	-267	-283	-269	-356
Annual Return On Assets	-58.57 %	-59.82 %	-57.45 %	-22.3 %	-34.65 %

SANA's 5 Years Annual ROA >> Back to SANA Management Effectiveness >> Compare SANA ROA to its Competitors

More Return On Assets Ratios
SANA's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SANA's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SANA's Competitors
Subscribers only: Roa for Sana Biotechnology Inc 's Suppliers
Subscribers only: Return On Assets for SANA's Customers

You may also want to know
SANA's Roi	SANA's Inventory Turnover Ratio	SANA's Growth Rates	SANA's Dividend Comparisons
	SANA's Profitability Ratios	SANA's Asset Turnover Ratio	SANA's Dividend Growth
SANA's Roe	SANA's Valuation Ratios	SANA's Financial Strength Ratios	SANA's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector

ROA

Date modified: 2026-11-09T06:47:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.